XML 52 R43.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies - Additional Information (Detail)
 12 Months Ended
Dec. 31, 2024
USD ($)
Segment
Dec. 31, 2023
USD ($)
Feb. 20, 2025
USD ($)
Accounting Policy [Line Items]      
Number of operating segment | Segment 1    
Highly liquid investment maturity period three months or less    
Cash and cash equivalents $ 50,482,000 $ 81,553,000  
Long-term investments 0    
Short-term investments $ 0 $ 121,898,000  
Short term investments maturity 12 months 12 months  
Long term Investments Maturity   12 months  
Available-for-sale debt securities $ 0    
Property and equipment 0 $ 4,785,000  
Operating leases 9,722,000 15,175,000  
Operating lease 0    
Impairment of long-lived assets 0 0  
Impairment of inatangible assets finite lived 0 0  
Accumulated deficit (1,889,499,000) (1,841,920,000)  
Accumulated other comprehensive loss $ (5,732,000) $ (6,875,000)  
FibroGen International [Member]      
Accounting Policy [Line Items]      
Description of discontinued operations On February 20, 2025, the Company entered into the Share Purchase Agreement with AstraZeneca Treasury Limited, pursuant to which FibroGen and its subsidiary FibroGen China Anemia Holdings, Ltd. agreed to sell all of the issued and outstanding equity interests of FibroGen International to AstraZeneca Treasury Limited for an aggregate purchase price comprised of $85 million in cash for the enterprise value of FibroGen International, plus an additional cash amount equal to the net cash held in China by FibroGen International and its subsidiaries as of the closing. This sale includes all of our roxadustat assets in China, including FibroGen International’s subsidiary FibroGen (China) Medical Technology Development Co., Ltd and its 51.1% interest in Falikang. The transaction is expected to close by mid-2025, and is subject to customary closing conditions and closing deliverables, including receipt of regulatory approval from the China State Administration for Market Regulation. The Company analyzed the quantitative and qualitative factors and concluded that the sale of FibroGen International represents a strategic shift in FibroGen’s business and qualified as a discontinued operation. As a result, Company determined that FibroGen International met the “held for sale” criteria and the “discontinued operations” criteria in accordance with FASB ASC 205, Presentation of Financial Statements, as of December 31, 2024. Accordingly, the operating results related to the FibroGen International are classified as discontinued operations, and have been reflected as discontinued operations in the consolidated statements of operations, while the related assets and liabilities were classified within the consolidated balance sheets as held for sale for all periods presented.    
Discontinued operations name FibroGen International    
AstraZeneca Agreements [Member]      
Accounting Policy [Line Items]      
Profit share percent 50.00%    
Minimum [Member] | Debt Financing Agreement [Member]      
Accounting Policy [Line Items]      
Unrestricted cash and cash equivalent balance required to maintain in accounts $ 30,000,000    
Minimum [Member] | Computer Equipment [Member]      
Accounting Policy [Line Items]      
Property and equipment estimated useful life 3 years    
Minimum [Member] | Laboratory Equipment [Member]      
Accounting Policy [Line Items]      
Property and equipment estimated useful life 3 years    
Minimum [Member] | Machinery [Member]      
Accounting Policy [Line Items]      
Property and equipment estimated useful life 3 years    
Minimum [Member] | Furniture and Fixtures [Member]      
Accounting Policy [Line Items]      
Property and equipment estimated useful life 3 years    
Maximum [Member] | Computer Equipment [Member]      
Accounting Policy [Line Items]      
Property and equipment estimated useful life 5 years    
Maximum [Member] | Laboratory Equipment [Member]      
Accounting Policy [Line Items]      
Property and equipment estimated useful life 5 years    
Maximum [Member] | Machinery [Member]      
Accounting Policy [Line Items]      
Property and equipment estimated useful life 5 years    
Maximum [Member] | Furniture and Fixtures [Member]      
Accounting Policy [Line Items]      
Property and equipment estimated useful life 5 years    
Subsequent Event [Member] | FibroGen International [Member]      
Accounting Policy [Line Items]      
Purchase price in cash     $ 85,000,000
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | Beijing Falikang Pharmaceutical Co. Ltd [Member] | AstraZenecaAB [Member]      
Accounting Policy [Line Items]      
Percentage of outstanding shares acquired 51.10%   51.10%